CtrlK
GEHC
NASDAQ
Health Care
$63.07
USD
-$2.63 (-4.00%)
At close: Jul 17, 2026, 4:00 PM EDT
Market Cap:
$29.89B
Volume:
6.4M
Previous Close
$65.70
Day Range
$62.64 - $66.28
52 Week Range
$58.75 - $89.77
Average Volume (10 Days)
5.2M
P/E Ratio (TTM)
15.65
Dividend Yield
0.21%
GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. The company is headquartered in Chicago, Illinois and currently employs 54,000 full-time employees. The company went IPO on 2022-12-15. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
CEO
Mr. Peter Arduini
Headquaters
Chicago, ILLINOIS, US
Founded
2022
Employees
54,000
GE HealthCare began dosing patients in a global trial for mangaciclanol, a manganese-based MRI contrast agent with FDA Fast Track designation. The trial explores an alternative to gadolinium-based agents amid growing safety and environmental concerns.
0
0
GE HealthCare has begun the LUMINA Phase 2/3 clinical trial for mangaciclanol, a manganese-based MRI contrast agent that received FDA Fast Track designation. The trial evaluates mangaciclanol as a potential alternative to gadolinium-based agents, which face growing scrutiny over safety and environmental concerns.
0
0
